Roche outlines R&D focus after Genentech integration
This article was originally published in Scrip
Roche is to expand its operations in oncology, metabolism, inflammation and central nervous system diseases in order to drive its profitability into 2015.
You may also be interested in...
Roche's CEO Severin Schwan says corporate nurturing and support consistently given by the pharma's founding families have helped him take the long view, even in difficult times.
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.